A new drug for NASH with liver scarring
Part of Digestive system clinical trials.
This study tests a new injected drug (TQA2225/AP025) that may help reduce liver fat and inflammation in people with NASH (a type of fatty liver disease with scarring). It’s for adults who have had a recent liver biopsy and MRI confirming NASH and moderate liver fat.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 74 years old.
- You must have had a liver biopsy showing NASH with some fibrosis (scarring) in the last 6 months.
- An MRI must show at least 10% fat in your liver.
- Your weight must have been stable (no more than 5% change) in the 6 weeks before the study.
- You cannot have cirrhosis or other causes of liver disease besides NASH.
- You cannot have poorly controlled diabetes, uncontrolled high blood pressure, or osteoporosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication for people with fatty liver disease. It will see if the drug can reduce liver fat and improve liver health over several doses.
This study is testing a new drug that targets thyroid hormone receptors in the liver, alone or combined with another drug, to reduce inflammation and scarring in people with MASH (a type of fatty liver disease). If you have MASH with moderate liver scarring and are otherwise healthy, this trial may help find a new treatment option.
This trial tests a new medicine, HSK31679, for people with MASH (a type of fatty liver disease with inflammation and scarring). It aims to see if the drug can help improve liver health.
This trial tests ADI-PEG 20 against a placebo (inactive pill) to see if it improves liver disease in people with NASH and compensated cirrhosis. It may help by targeting liver fat and inflammation seen on scans and biopsy.
This trial tests an experimental pill called CS060380 for people with NASH (a type of fatty liver disease that can cause liver damage). You may qualify if you have a liver biopsy showing NASH with early-to-moderate scarring, or an MRI showing at least 10% liver fat, and your liver enzymes are stable.
This study tests a new medicine, efruxifermin, for people with NASH/MASH (fatty liver disease) and moderate liver scarring. It aims to see if the drug can help improve the liver's condition.
Hear when a new Non-alcoholic Steatohepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.